Europe Frontotemporal Dementia Market By Drug Class Type (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Others), By Disease Type (Frontotemporal Dementia, Primary Progressive Aphasia Others), By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others), By Country, Competition, Forecast & Opportunities, 2028
Europe frontotemporal dementia market is expected to witness significant growth during the forecast period 2024-2028. The growing prevalence of dementia, along with the growing aging population in the region, is anticipated to facilitate the growth of the market. The gradual increase in the number of new cases of dementia registered directly every year is strengthening the growth of the frontotemporal dementia market. Moreover, the rising funding provided by the government as well as by several non-profit organizations for the target disease care, support, and R&D activities to develop new drugs are the major factor propelling the growth of the market. Furthermore, the advent of novel Frontotemporal dementia therapies as well as new diagnosing biomarkers, are projected to augment the growth of the market. The rising number of clinical trials in the region is propelling the growth of the market.
Frontotemporal dementia refers to a group of uncommon brain disorders that primarily affect the frontal and temporal lobes of the brain. These areas of the brain are generally associated with personality, behavior, and language. It often begins between the age of 40 and 65.
Growing Prevalence of Dementia
The growing incidence of dementia among European people is likely to impel the growth of the market. In 2019, the occurrence of dementia in Europe was roughly 188 per 100,000 population. The growing geriatric population is more susceptible to dementia than the younger generation due to their rising age, which, in turn, is projected to propel the growth of the market. In 2019, about 45 percent of women and 30 percent of men aged 90 years and above were living with dementia in Europe. Generally, the share of women living with dementia in Europe was much higher when compared to men.
Increasing Number of Clinical Trials
There is a large number of clinical studies which are going on for frontotemporal dementia in the region, which is projected to bolster the growth of the market. There is a total of 25 clinical studies which are completed in Europe. For instance, in 2019, a clinical trial for the device named transcranial direct current stimulation (tDCS) was completed under the study name “Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia.”
Recent Developments
Europe frontotemporal dementia market is segmented into drug class type, disease type, end user, and region. Based on drug class type, the market is divided into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. Based on disease type, the market is bifurcated into frontotemporal dementia, primary progressive aphasia, and others. Based on end users, the market is divided into hospitals & clinics, ambulatory surgery centers, and others. In terms of countries, the market is categorized into France, Germany, United Kingdom, Italy, Spain, Belgium, Netherlands, Switzerland, Poland, and Sweden.
Market Players
GlaxoSmithKline PLC, Eli Lilly Italia S.p.A., Pfizer Deutschland GmbH., F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca GmbH, Sanofi S.A, Allergen plc, Johnson & Johnson and Viatris Inc are some of the leading companies operating in the Europe Frontotemporal Dementia market.
Report Scope:
In this report, Europe frontotemporal dementia market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Europe frontotemporal dementia market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Frontotemporal dementia refers to a group of uncommon brain disorders that primarily affect the frontal and temporal lobes of the brain. These areas of the brain are generally associated with personality, behavior, and language. It often begins between the age of 40 and 65.
Growing Prevalence of Dementia
The growing incidence of dementia among European people is likely to impel the growth of the market. In 2019, the occurrence of dementia in Europe was roughly 188 per 100,000 population. The growing geriatric population is more susceptible to dementia than the younger generation due to their rising age, which, in turn, is projected to propel the growth of the market. In 2019, about 45 percent of women and 30 percent of men aged 90 years and above were living with dementia in Europe. Generally, the share of women living with dementia in Europe was much higher when compared to men.
Increasing Number of Clinical Trials
There is a large number of clinical studies which are going on for frontotemporal dementia in the region, which is projected to bolster the growth of the market. There is a total of 25 clinical studies which are completed in Europe. For instance, in 2019, a clinical trial for the device named transcranial direct current stimulation (tDCS) was completed under the study name “Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia.”
Recent Developments
- In 2022, AviadoBio, a pioneering, pre-clinical stage gene therapy company that emphasized developing and delivering transformative medicines for patients with neurodegenerative disorders, announced that both the U.S. Food and Drug Administration (FDA) and the European Commission (EC) had granted orphan designation to AVB-101, a one-time gene therapy for the treatment of frontotemporal dementia (FTD).
- In 2021, Centogene N.V., a commercial-stage company that emphasized producing data-driven insights to diagnose, understand, and treat rare diseases, announced that they had enrolled the first patient in the international EFRONT Study, an observational study to know the prevalence of genetic mutations in patients with frontotemporal dementia (FTD).
Europe frontotemporal dementia market is segmented into drug class type, disease type, end user, and region. Based on drug class type, the market is divided into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. Based on disease type, the market is bifurcated into frontotemporal dementia, primary progressive aphasia, and others. Based on end users, the market is divided into hospitals & clinics, ambulatory surgery centers, and others. In terms of countries, the market is categorized into France, Germany, United Kingdom, Italy, Spain, Belgium, Netherlands, Switzerland, Poland, and Sweden.
Market Players
GlaxoSmithKline PLC, Eli Lilly Italia S.p.A., Pfizer Deutschland GmbH., F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca GmbH, Sanofi S.A, Allergen plc, Johnson & Johnson and Viatris Inc are some of the leading companies operating in the Europe Frontotemporal Dementia market.
Report Scope:
In this report, Europe frontotemporal dementia market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Europe Frontotemporal Dementia Market, By Drug Class Type:
- Cognitive Enhancers
- Antipsychotics
- Antidepressants
- CNS Stimulants
- Others
- Europe Frontotemporal Dementia Market, By Disease Type:
- Frontotemporal Dementia
- Primary Progressive Aphasia
- Others
- Europe Frontotemporal Dementia Market, By End User:
- Hospitals & Clinics
- Ambulatory Surgery Centers
- Others
- Europe Frontotemporal Dementia Market, By Country:
- France
- Germany
- United Kingdom
- Italy
- Spain
- Belgium
- Netherlands
- Switzerland
- Poland
- Sweden
Company Profiles: Detailed analysis of the major companies present in Europe frontotemporal dementia market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
- Profit margin analysis in the case of the direct and indirect sales channels.
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. EUROPE FRONTOTEMPORAL DEMENTIA MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class Type (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Others)
5.2.2. By Disease Type (Frontotemporal Dementia, Primary Progressive Aphasia, Others)
5.2.3. By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others)
5.2.4. By Company (2022)
5.2.5. By Country
5.3. Market Map
5.3.1. By Drug Class Type
5.3.2. By Disease Type
5.3.3. By End User
5.3.4. By Country
5.4. Europe: Country Analysis
5.4.1. Germany Frontotemporal Dementia Market Outlook
5.4.1.1. Market Size & Forecast
5.4.1.1.1. By Value
5.4.1.2. Market Share & Forecast
5.4.1.2.1. By Drug Class Type
5.4.1.2.2. By Disease Type
5.4.1.2.3. By End User
5.4.2. France Frontotemporal Dementia Market Outlook
5.4.2.1. Market Size & Forecast
5.4.2.1.1. By Value
5.4.2.2. Market Share & Forecast
5.4.2.2.1. By Drug Class Type
5.4.2.2.2. By Disease Type
5.4.2.2.3. By End User
5.4.3. United Kingdom Frontotemporal Dementia Market Outlook
5.4.3.1. Market Size & Forecast
5.4.3.1.1. By Value
5.4.3.2. Market Share & Forecast
5.4.3.2.1. By Drug Class Type
5.4.3.2.2. By Disease Type
5.4.3.2.3. By End User
5.4.4. Italy Frontotemporal Dementia Market Outlook
5.4.4.1. Market Size & Forecast
5.4.4.1.1. By Value
5.4.4.2. Market Share & Forecast
5.4.4.2.1. By Drug Class Type
5.4.4.2.2. By Disease Type
5.4.4.2.3. By End User
5.4.5. Spain Frontotemporal Dementia Market Outlook
5.4.5.1. Market Size & Forecast
5.4.5.1.1. By Value
5.4.5.2. Market Share & Forecast
5.4.5.2.1. By Drug Class Type
5.4.5.2.2. By Disease Type
5.4.5.2.3. By End User
5.4.6. Belgium Frontotemporal Dementia Market Outlook
5.4.6.1. Market Size & Forecast
5.4.6.1.1. By Value
5.4.6.2. Market Share & Forecast
5.4.6.2.1. By Drug Class Type
5.4.6.2.2. By Disease Type
5.4.6.2.3. By End User
5.4.7. Netherlands Frontotemporal Dementia Market Outlook
5.4.7.1. Market Size & Forecast
5.4.7.1.1. By Value
5.4.7.2. Market Share & Forecast
5.4.7.2.1. By Drug Class Type
5.4.7.2.2. By Disease Type
5.4.7.2.3. By End User
5.4.8. Switzerland Frontotemporal dementia Market Outlook
5.4.8.1. Market Size & Forecast
5.4.8.1.1. By Value
5.4.8.2. Market Share & Forecast
5.4.8.2.1. By Drug Class Type
5.4.8.2.2. By Disease Type
5.4.8.2.3. By End User
5.4.9. Poland Frontotemporal dementia Market Outlook
5.4.9.1. Market Size & Forecast
5.4.9.1.1. By Value
5.4.9.2. Market Share & Forecast
5.4.9.2.1. By Drug Class Type
5.4.9.2.2. By Disease Type
5.4.9.2.3. By End User
5.4.10. Sweden Frontotemporal dementia Market Outlook
5.4.10.1. Market Size & Forecast
5.4.10.1.1. By Value
5.4.10.2. Market Share & Forecast
5.4.10.2.1. By Drug Class Type
5.4.10.2.2. By Disease Type
5.4.10.2.3. By End User
6. MARKET DYNAMICS
6.1. Drivers
6.2. Challenges
7. MARKET TRENDS & DEVELOPMENTS
8. COMPETITIVE LANDSCAPE
8.1. Business Overview
8.2. Product Offerings
8.3. Recent Developments
8.4. Financials (As Reported)
8.5. Key Personnel
8.6. SWOT Analysis
8.6.1. GlaxoSmithKline PLC
8.6.2. Eli Lilly Italia - S.P.A.
8.6.3. Pfizer Deutschland GmbH.
8.6.4. F. Hoffmann-La Roche Ltd.
8.6.5. Novartis AG
8.6.6. AstraZeneca GmbH
8.6.7. Sanofi S.A
8.6.8. Allergen plc
8.6.9. Johnson & Johnson
8.6.10. Viatris Inc.
9. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. EUROPE FRONTOTEMPORAL DEMENTIA MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class Type (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Others)
5.2.2. By Disease Type (Frontotemporal Dementia, Primary Progressive Aphasia, Others)
5.2.3. By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others)
5.2.4. By Company (2022)
5.2.5. By Country
5.3. Market Map
5.3.1. By Drug Class Type
5.3.2. By Disease Type
5.3.3. By End User
5.3.4. By Country
5.4. Europe: Country Analysis
5.4.1. Germany Frontotemporal Dementia Market Outlook
5.4.1.1. Market Size & Forecast
5.4.1.1.1. By Value
5.4.1.2. Market Share & Forecast
5.4.1.2.1. By Drug Class Type
5.4.1.2.2. By Disease Type
5.4.1.2.3. By End User
5.4.2. France Frontotemporal Dementia Market Outlook
5.4.2.1. Market Size & Forecast
5.4.2.1.1. By Value
5.4.2.2. Market Share & Forecast
5.4.2.2.1. By Drug Class Type
5.4.2.2.2. By Disease Type
5.4.2.2.3. By End User
5.4.3. United Kingdom Frontotemporal Dementia Market Outlook
5.4.3.1. Market Size & Forecast
5.4.3.1.1. By Value
5.4.3.2. Market Share & Forecast
5.4.3.2.1. By Drug Class Type
5.4.3.2.2. By Disease Type
5.4.3.2.3. By End User
5.4.4. Italy Frontotemporal Dementia Market Outlook
5.4.4.1. Market Size & Forecast
5.4.4.1.1. By Value
5.4.4.2. Market Share & Forecast
5.4.4.2.1. By Drug Class Type
5.4.4.2.2. By Disease Type
5.4.4.2.3. By End User
5.4.5. Spain Frontotemporal Dementia Market Outlook
5.4.5.1. Market Size & Forecast
5.4.5.1.1. By Value
5.4.5.2. Market Share & Forecast
5.4.5.2.1. By Drug Class Type
5.4.5.2.2. By Disease Type
5.4.5.2.3. By End User
5.4.6. Belgium Frontotemporal Dementia Market Outlook
5.4.6.1. Market Size & Forecast
5.4.6.1.1. By Value
5.4.6.2. Market Share & Forecast
5.4.6.2.1. By Drug Class Type
5.4.6.2.2. By Disease Type
5.4.6.2.3. By End User
5.4.7. Netherlands Frontotemporal Dementia Market Outlook
5.4.7.1. Market Size & Forecast
5.4.7.1.1. By Value
5.4.7.2. Market Share & Forecast
5.4.7.2.1. By Drug Class Type
5.4.7.2.2. By Disease Type
5.4.7.2.3. By End User
5.4.8. Switzerland Frontotemporal dementia Market Outlook
5.4.8.1. Market Size & Forecast
5.4.8.1.1. By Value
5.4.8.2. Market Share & Forecast
5.4.8.2.1. By Drug Class Type
5.4.8.2.2. By Disease Type
5.4.8.2.3. By End User
5.4.9. Poland Frontotemporal dementia Market Outlook
5.4.9.1. Market Size & Forecast
5.4.9.1.1. By Value
5.4.9.2. Market Share & Forecast
5.4.9.2.1. By Drug Class Type
5.4.9.2.2. By Disease Type
5.4.9.2.3. By End User
5.4.10. Sweden Frontotemporal dementia Market Outlook
5.4.10.1. Market Size & Forecast
5.4.10.1.1. By Value
5.4.10.2. Market Share & Forecast
5.4.10.2.1. By Drug Class Type
5.4.10.2.2. By Disease Type
5.4.10.2.3. By End User
6. MARKET DYNAMICS
6.1. Drivers
6.2. Challenges
7. MARKET TRENDS & DEVELOPMENTS
8. COMPETITIVE LANDSCAPE
8.1. Business Overview
8.2. Product Offerings
8.3. Recent Developments
8.4. Financials (As Reported)
8.5. Key Personnel
8.6. SWOT Analysis
8.6.1. GlaxoSmithKline PLC
8.6.2. Eli Lilly Italia - S.P.A.
8.6.3. Pfizer Deutschland GmbH.
8.6.4. F. Hoffmann-La Roche Ltd.
8.6.5. Novartis AG
8.6.6. AstraZeneca GmbH
8.6.7. Sanofi S.A
8.6.8. Allergen plc
8.6.9. Johnson & Johnson
8.6.10. Viatris Inc.
9. STRATEGIC RECOMMENDATIONS
